Use of crushed tranexamic acid tablets in water for paediatric patients with bleeding disorders

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia 2024-05, Vol.30 (3), p.648-657
• Main Authors: Al-Huniti, Ahmad, Marshall, Linda, Rusk, Dawn, Pruthi, Rajiv K, Rodriguez, Vilmarie, Ferdjallah, Asmaa, Kuhn, Alexis
• Format: Article
• Language: English
• Subjects: Antifibrinolytic agents; Antifibrinolytic Agents - administration & dosage; Antifibrinolytic Agents - therapeutic use; Bleeding; Blood Coagulation Disorders - drug therapy; Child; Child, Preschool; Children; Female; Hemophilia; Hemorrhage - drug therapy; Humans; Infant; Male; Patients; Pediatrics; Retrospective Studies; Tablets; Tranexamic Acid - administration & dosage; Tranexamic Acid - therapeutic use; Water
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1111/hae.14996

Ε-Aminocaproic acid oral solution (EACA OS) is the only commercially available antifibrinolytic for patients who cannot swallow tablets. Insurance denials and high costs remain barriers to its use. To determine the safety and efficacy of crushed tranexamic acid tablets in water (cTXAw) for children with bleeding disorders. We retrospectively reviewed records of children ( .1). No patients had adverse effects. Eight of 19 patients (42%) who were initially prescribed EACA OS did not receive it because of cost or insurance denial. The estimated average wholesale price of one treatment was $94 for cTXAw and $905 for EACA OS. CTXAw appears to be an effective, safe, and low-cost alternative option to EACA OS for young children with bleeding disorders.